Company intelligence / Profile preview
Coegin Pharma
Lund, Swedencoeginpharma.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
AVX001 GEL is in Phase 2 clinical study for actinic keratosis and Phase 1 for basal cell carcinoma. AVX420 is in preclinical study for leukemia. FOL026 is in preclinical study for cardiovascular complications in diabetes. AVX420/FOL026 therapy is in preclinical study for kidney and liver fibrosis. FOL005 is being developed for stimulation of hair growth.
- Therapeutic areas
- OncologyCardiovascularDermatologyNephrology
- Modalities
- Small moleculespeptide-based drugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Coegin Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coegin Pharma.